Journal Article

IL4Rα and IL17A Blockade Rescue Autoinflammation in SOCS1 Haploinsufficiency

Gruber, Conor, Ho, Hsi-en, Lee, Angelica, Khattri, Saakshi, Frost, Jacqueline M, Bowcock, Anne M, Bogunovic, Dusan, Buta, Sofija, Gottlieb, Alice B

2024

Overview

By inhibition of JAK-STAT signaling, SOCS1 acts as a master regulator of the cytokine response across numerous tissue types and cytokine pathways. Haploinsufficiency of SOCS1 has recently emerged as a monogenic immunodysregulatory disease with marked clinical variability. Here, we describe a patient with severe dermatitis, recurrent skin infections, and psoriatic arthritis that harbors a novel heterozygous mutation in SOCS1. The variant, c.202_203delAC, generates a frameshift in SOCS1, p.Thr68fsAla*49, which leads to complete loss of protein expression. Unlike WT SOCS1, Thr68fs SOCS1 fails to inhibit JAK-STAT signaling when expressed in vitro. The peripheral immune signature from this patient was marked by a redistribution of monocyte sub-populations and hyper-responsiveness to multiple cytokines. Despite this broad hyper-response across multiple cytokine pathways in SOCS1 haploinsufficiency, the patient’s clinical disease was markedly responsive to targeted IL4Rα- and IL17-blocking therapy. In accordance, the mutant allele was unable to regulate IL4Rα signaling. Further, patient cells were unresponsive to IL4/IL13 while on monoclonal antibody therapy. Together, this study reports a novel SOCS1 mutation and suggests that IL4Rα blockade may serve as an unexpected, but fruitful therapeutic target for some patients with SOCS1 haploinsufficiency.

• Publisher: Springer Nature B.V
• Subject: Cytokines / Dermatitis / Haploinsufficiency / Immunotherapy / Monoclonal antibodies / Monocytes / Mutation / Psoriatic arthritis / Signal transduction / Therapeutic targets